188891-13-6

Basic information

• Product Name: Acetic acid, (4-acetyl-2-methoxy-5-nitrophenoxy)-
• CAS NO: 188891-13-6
• Molecular Formula: C11H11NO7
• Molecular Weight: 269.211
• Mol File: 188891-13-6.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Acetic acid, (4-acetyl-2-methoxy-5-nitrophenoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, (4-acetyl-2-methoxy-5-nitrophenoxy)-(188891-13-6)
• EPA Substance Registry System: Acetic acid, (4-acetyl-2-methoxy-5-nitrophenoxy)-(188891-13-6)

Safety Data

• Hazardous Substances Data: 188891-13-6(Hazardous Substances Data)

Upstream product

• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 188891-12-5 (4-acetyl-2-methoxy-phenoxy)acetic acid tert-butyl ester 

Downstream Products

• 890404-56-5 N-(3-(4-acetyl-2-methoxy-5-nitrophenoxy)acetamide)propyl methacrylamide 
• 1262298-74-7 (E/Z)-N-cyclododecyl-2-(4-(1-hydrazonoethyl)-2-methoxy-5-nitrophenoxy)acetamide 
• 1262298-75-8 N-cyclododecyl-2-(4-(1-diazoethyl)-2-methoxy-5-nitrophenoxy)acetamide 

Relevant articles and documents

UV-induced photolysis of polyurethanes

Waste production associated with the use of non-degradable materials in packaging is a growing cause of environmental concern, with the polyurethane (PU) class being notorious for their lack of degradability. Herein, we incorporate photosensitiveortho-Nitrobenzyl units into PUs to achieve controllable photodegradability. We performed their photolysis in solution and thin films which can inform the design of degradable adhesives.

Light Control of Protein Solubility Through Isoelectric Point Modulation

We previously described the photoactivated depot or PAD approach that allows for the light control of therapeutic protein release. This approach relies on the ability to use light to change a protein's solubility. Traditionally this was accomplished by li

PHOTOCLEAVABLE DRUG CONJUGATES

Novel photocleavable drug conjugates for forming drug depots comprise drugs attached to photocleavable groups. In one embodiment, the drug is linked via photocleavable group(s) to a polymer chain to form a photocleavable drug-polymer conjugate that generally forms the depot matrix. In another embodiment, the drug is crosslinked via photocleavable group(s) to themselves to form a photocleavable drug conjugate that generally forms the depot.